Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference 2019

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company,
announced that Alan H. Auerbach, Chairman, Chief Executive Officer,
President and Founder of Puma, will provide an overview of the Company
at 3:00 p.m. PDT on Wednesday, May 15, at the Bank of America Merrill
Lynch Health Care Conference 2019. The conference will be held at Encore
at the Wynn in Las Vegas.

A live webcast of the presentation will be available on the Company’s
website at www.pumabiotechnology.com.
The presentation will be archived on the website and available for 30

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on
the development and commercialization of innovative products to enhance
cancer care. Puma in-licenses the global development and
commercialization rights to three drug candidates — PB272 (neratinib,
oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was
approved by the U.S. Food and Drug Administration in July 2017 for the
extended adjuvant treatment of adult patients with early stage
HER2-overexpressed/amplified breast cancer, following adjuvant
trastuzumab-based therapy, and is marketed in the United States as
NERLYNX® (neratinib) tablets. NERLYNX was granted marketing
authorization by the European Commission in September 2018 for the
extended adjuvant treatment of adult patients with early stage hormone
receptor-positive HER2-overexpressed/amplified breast cancer and who are
less than one year from completion of prior adjuvant trastuzumab-based
therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.

Further information about Puma Biotechnology may be found at www.pumabiotechnology.com.


Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc.,

David Schull or Juliette Gorson, Russo Partners, +1-212-845-4271 /

Sky Optics Media drone video